Commentary|Videos|March 13, 2025
Key Prostate Cancer Updates to Emerge From ASCO GU 2025
Author(s)Daniel J. George, MD, Matthew Smith, MD, PhD
Daniel J. George, MD, and Matthew Smith, MD, PhD, discuss other key prostate cancer data presented at ASCO GU 2025.
Advertisement
Episodes in this series
Advertisement
Related to this article
Mark Garzotto, MD, discusses data with aglatimagene besadenovec plus valacyclovir and EBRT in intermediate- to high-risk localized prostate cancer.
In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.
GE HealthCare and Mayo Clinic announced a novel theranostics study to explore a personalized approach to radioligand therapy for advanced prostate cancer.
The addition of olaparib to radium‐223 did not significantly impact PROs compared with radium‐223 alone in mCRPC with bone metastases.
Advertisement
Advertisement
Trending on OncLive
1
Experts Unpack Crucial Hematologic Oncology Data From ASCO 2026
2
International Intel: A Glance at the Top Global Breast Cancer News From April-June 2026
3
MYTHOS Misses Prespecified ORR End Point With T-DXd in HER2-Low Salivary Gland Carcinoma
4
Subcutaneous Pembrolizumab Faces Scrutiny Over Convenience and Cost for Patients With Cancer
5